Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management

PHASE4TerminatedINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

October 8, 2020

Primary Completion Date

March 9, 2023

Study Completion Date

June 3, 2023

Conditions
Hyperkalemia
Interventions
DRUG

Patiromer Powder for Oral Suspension [Veltassa]

Powder will be mixed with a liquid (water, apple or cranberry juice) and given to patient to drink

DRUG

Placebo

Powder will be mixed with a liquid (water, apple or cranberry juice) and given to patient to drink

Trial Locations (19)

10029

Mt Sinai. Icahn School of Medicine, New York

11219

Maimonides Medical Center, New York

11794

Stony Brook University Hospital, Stony Brook

19718

Christiana Care, Newark

20037

George Washington University, Washington D.C.

27157

Wake Forest University Health Sciences, Winston-Salem

39216

University of Mississippi Medical Center, Jackson

43210

Ohio State University. Wexner Medical Center, Columbus

45219

University of Cincinnati, Cincinnati

48201

Wayne State University, Detroit

48202

Henry Ford Hospital, Detroit

55415

Hennepin Healthcare Research Institute, Minneapolis

63110

Washington University of St Louis, St Louis

76104

JPS Health Network, Fort Worth

77030

Baylor College of Medicine, Houston

UT Memorial Hermann Hospital, Houston

94305

Stanford University School of Medicine, Stanford

06519

Yale University, New Haven

01199

Baystate Medical Center, Springfield

All Listed Sponsors
lead

Comprehensive Research Associates

INDUSTRY